← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

MOULDER LEON O JR

Chief Executive Officer | Officer | See Remarks

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001228865

Purchase history

Companies traded
1
Purchases · 12M
5
Purchases · 24M
9
Average purchase
$840.8K
Median purchase
$1.0M
Gross purchase value
$7.6M

Companies: Zenas BioPharma, Inc.

9 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2026-05-18Zenas BioPharma, Inc.ZBIOChief Executive Officer | Officer$1.0MOpen filing
2026-04-29Zenas BioPharma, Inc.ZBIOChief Executive Officer | Officer$1.1MOpen filing
2026-03-31Zenas BioPharma, Inc.ZBIOChief Executive Officer | Officer$1.0MOpen filing
2026-02-03Zenas BioPharma, Inc.ZBIOChief Executive Officer | Officer$1.0MOpen filing
2026-01-09Zenas BioPharma, Inc.ZBIOChief Executive Officer | Officer$1.6MOpen filing
2025-10-09Zenas BioPharma, Inc.ZBIOSee Remarks$769.9KOpen filing
2025-02-19Zenas BioPharma, Inc.ZBIOChief Executive Officer | Officer$166.8KOpen filing
2024-12-04Zenas BioPharma, Inc.ZBIOChief Executive Officer | Officer$718.1KOpen filing
2024-11-20Zenas BioPharma, Inc.ZBIOChief Executive Officer | Officer$148.9KOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

No completed point-in-time price outcome is available yet.

Research patterns

First purchase in 12M
0/8
Large purchase ≥ $100k
9/9
Cluster buying · 15D
3/9
Buying the dip
0/—

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.